Aethlon Medical (AEMD) CEO Note: A Novel Strategy To Address Ebola
SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
The current ebola outbreak in West Africa demonstrates the urgent need for therapeutic strategies to defend against emerging pandemic threats. It also highlights why the Department of Health and Human Services (HHS) has shifted the focus of government biodefense and pandemic threat initiatives toward broad-spectrum therapies able to target multiple pathogens. At present, a majority of all infectious viruses are not addressed by drug therapies, which are designed to inhibit or block replication of a single viral species.
At Aethlon Medical, we are intersecting advanced biology with modern plasma membrane technology to rethink the treatment of viral pathogens. The result is the Aethlon Hemopurifier®, a therapeutic device that has been validated to capture a broad-spectrum of viral pathogens and immunosuppressive proteins through affinity binding to a unique high-mannose structure that is co-opted from the host (the infected individual) as a means for viruses to evade detection of the host immune system. We have also discovered that this signature exists on tumor-secreted exosomes that promote cancer progression.
We believe our Hemopurifier® is the most advanced and perhaps only true broad-spectrum countermeasure against emerging pandemic threats such as ebola, and viral threats that could be weaponized to purposely infect civilian and military populations. Our belief is supported by human clinical outcomes and supporting in vitro studies conducted at leading government and non- government labs.
There is no money in creating specific anti-viral medications. The drugs or devices need to be broad - spectrum medications and devices because the viruses mutate so quickly. Drugs are only effective for the one strain/genetic type it was developed to counter. Broad - spectrum medications or devices will give the body more time to develop its own mechanisms to fight the virus by reducing the cytokine storm effect that might be the real killer. As stated by Dr Ribner treating the Ebola infected Drs in the Atlanta:
"We just have to keep the patient alive long enough in order for the body to control this infection," Ribner explained. JMHO GLTYA